This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by FOSTER, C. M. Articles by CUTLER, G. B. Search for Related Content PubMed PubMed Citation Articles by FOSTER, C. M. Articles by CUTLER, G. B., JR.

Variable Response to a Long-Acting Agonist of Luteinizing Hormone-Releasing Hormone in Girls with McCune-Albright Syndrome

Laboratory of Developmental Pharmacology National Institute of Child Health and Human Development, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20205
The Developmental Endocrinology Branch National Institute of Child Health and Human Development, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20205

Address all correspondence and requests for reprints to: Carol M. Foster, M.D., Building 10, Room 10B09, National Institutes of Health, Bethesda, Maryland 20205.

Six girls with McCune-Albright syndrome were treated for at least 2 months with the long-acting LHRH agonist D-Trp⁶-Pro⁹-NEt-LHRH, which previously was found to be an effective treatment for true precocious puberty. Nocturnal and LHRH-stimulated serum gonadotropin levels and plasma estradiol levels were measured before treatment and after 2–3 months of treatment. Five of the six girls had no decrease in serum gonadotropin or plasma estradiol levels during therapy, and their pubertal signs were unaffected by treatment. All five of these girls had serum gonadotropin levels that were within or below the normal prepubertal range. The sixth girl, who had gonadotropin levels in the normal pubertal range before treatment, had decreased serum gonadotropin and plasma estradiol levels during 1 yr of LHRH analog therapy. This was associated with cessation of menses and regression of secondary sexual changes. The failure of LHRH analog to modify the course of precocious puberty in the five patients with prepubertal serum gonadotropin concentrations is further evidence that the mechanism of precocious puberty in most girls with McCune-Albright syndrome differs from that in patients with true precocious puberty.

Received May 28, 1984.

This article has been cited by other articles:

				P. Feuillan, K. Calis, S. Hill, T. Shawker, P. G. Robey, and M. T. Collins Letrozole Treatment of Precocious Puberty in Girls with the McCune-Albright Syndrome: A Pilot Study J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2100 - 2106. [Abstract] [Full Text] [PDF]

				S. B. Nunez, K. Calis, G. B. Cutler Jr., J. Jones, and P. P. Feuillan Lack of Efficacy of Fadrozole in Treating Precocious Puberty in Girls with the McCune-Albright Syndrome J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5730 - 5733. [Abstract] [Full Text] [PDF]

				J. Gromoll, C.-J. Partsch, M. Simoni, V. Nordhoff, W. G. Sippell, E. Nieschlag, and B. B. Saxena A Mutation in the First Transmembrane Domain of the Lutropin Receptor Causes Male Precocious Puberty J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 476 - 480. [Abstract] [Full Text]

				G. B. CUTLER Jr., A. R. HOFFMAN, R. S. SWERDLOFF, R. J. SANTEN, D. R. MELDRUM, and F. COMITE Therapeutic Applications of Luteinizing-Hormone-Releasing Hormone and Its Analogs Ann Intern Med, May 1, 1985; 102(5): 643 - 657. [Abstract] [PDF]